GENERAL COMMENTARY article

Front. Endocrinol., 09 June 2015

Sec. Cancer Endocrinology

Volume 6 - 2015 | https://doi.org/10.3389/fendo.2015.00098

Corrigendum: “Cancer Cell Gene Expression Modulated from Plasma Membrane Integrin αvβ3 by Thyroid Hormone and Nanoparticulate Tetrac”

  • 1. Department of Medicine, Albany Medical College, Albany, NY, USA

  • 2. Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA

  • 3. Stanford University, Palo Alto, CA, USA

  • 4. Taipei Medical University, Taipei, Taiwan

  • 5. Rhode Island Nuclear Science Center, Narragansett, RI, USA

  • 6. Cleveland Clinic, Cleveland, OH, USA

  • 7. Hematology Institute and Blood Bank, Meir Medical Center, Kfar-Saba, Israel

  • 8. Department of Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

  • 9. Department of Sciences, University Roma Tre, Rome, Italy

In Table 2, the section designated “Disabling of cell survival pathway gene expression,” line 5 incorrectly states “…pro-apoptotic miR-21”; the correct statement is “…pro-apoptotic miR-15A.” The issue is correctly discussed in the body of the published text, p. 2, right column, paragraph 4.

Statements

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Summary

Keywords

integrin, thyroid hormone, tetraiodothyroacetic acid (tetrac), nano particle, gene expression, corrigendum

Citation

Davis PJ, Glinsky GV, Lin H-Y, Leith JT, Hercbergs A, Tang H-Y, Ashur-Fabian O, Incerpi S and Mousa SA (2015) Corrigendum: “Cancer Cell Gene Expression Modulated from Plasma Membrane Integrin αvβ3 by Thyroid Hormone and Nanoparticulate Tetrac”. Front. Endocrinol. 6:98. doi: 10.3389/fendo.2015.00098

Received

27 May 2015

Accepted

27 May 2015

Published

09 June 2015

Volume

6 - 2015

Edited by

Wen Zhou, Columbia University, USA

Reviewed by

Jean-Yves Scoazec, Université Lyon 1, France

Copyright

*Correspondence: Paul J. Davis,

Specialty section: This article was submitted to Cancer Endocrinology, a section of the journal Frontiers in Endocrinology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics